Mindfulness, Yoga, and Cardiovascular Disease

Not Applicable

Completed

• Conditions: Cardiovascular Disease; Stress; Anxiety; Depression
• Interventions: Behavioral: Mindfulness Meditation; Behavioral: Yoga; Behavioral: Exercise, Relaxation, and Health Education

• Registration Number: NCT00696852
• Lead Sponsor: The Cleveland Clinic

Brief Summary

In this study, we will conduct a preliminary, yet comprehensive evaluation of Mindfulness and Yoga, as compared to an exercise and education-based stress-reduction program. and simultaneous evaluation of the effect of an 8 week program of Mindfulness, 12 weeks of Yoga practice, and 12 weeks of an exercise and education-based program.

105 otherwise healthy individuals, who have cardiovascular risk factors and mild to moderate stress or anxiety will be randomly assigned to one of the three intervention groups: an 8 week program of Mindfulness, 12 week program of Yoga practice, and 12 week exercise and education-based group program. All subjects will perform daily practice that will continue after the weekly sessions end, allowing a follow up assessment at 24 weeks. Self-reported mood and psychological distress and physiological indicators of function of the ANS and stress hormones will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks. Blood and urine samples will be collected at baseline and 8 weeks to determine levels inflammatory and atherosclerosis markers.

We anticipate that the study will provide information on the efficacy of the Mindfulness and Yoga interventions as stress-reduction practices, variability in potential markers for activation of the brain/cardiovascular system connections, and preliminary estimates of effect size for each of these markers. Thus, the study will provide the data needed for designing a future study that will rigorously address these questions in a larger, randomized trial of Mindfulness and Yoga in patients with cardiovascular risk.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-06-11
• Study First Submitted QC: 2008-06-12
• Study First Posted: 2008-06-13
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-20
• Last Update Posted: 2012-09-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• between the age of 40 and 75
• A Framingham score >10
• A DASS-21 anxiety score >5
• A DASS-21 stress score >10
• A DASS-21 depression score > than 6
• A systolic blood pressure > 140
• A diastolic blood pressure > 90
• Diagnosed with diabetes
• Willing to accept randomization into and participation in one of the three intervention programs: Mindfulness, Yoga, or Conventional Stress Reduction

Exclusion Criteria

• Already practicing Mindfulness, Yoga, or similar meditative mind-body practices on a weekly basis
• Already enrolled in a lifestyle modification program including exercise or diet program
• Yoga or meditation be incompatible with religious or philosophical beliefs
• Experienced a major stressful life event in the last three months prior to the beginning of the intervention that is likely to affect the outcomes of the study
• Currently being treated or on medications for psychiatric conditions, including depression, anxiety, anger, or hostility
• A depression score >20 on the DASS-21 questionnaire
• A history of myocardial disease, peripheral vascular disease, cerebrovascular disease, atrial fibrillation, pacemaker placement, heart failure, valvular heart disease, congenital heart disease, Wolf-Parkinson White Syndrome, cardiomyopathy, or severe left ventricular systolic dysfunction
• Take melatonin supplements or any herbal supplement that contains melatonin or 5-LO inhibitors (turmeric, curcumin, ginger and frankincense herbal extracts)
• Currently using any drugs that contain beta-adrenergic blocking agents, beta-agonists, glucocorticoids, psychotropic medications, drugs that block 5-LO pathway (zileuton, monetlukast), TNF-a blocking agents (infliximab, etanercept, adalimumab)
• A planned change in blood pressure, anticoagulant medication and lipids lower agents (such as aspirin, statin and plavix) 1 month prior and during the intervention
• Asthma, obstructive pulmonary disease, or any other respiratory disease
• Pregnant or breastfeeding
• An active/chronic infection, cancer, connective tissue, or other inflammatory disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Mindfulness Meditation	Mindfulness Meditation	-
Yoga	Yoga	-
Conventional Stress Reduction	Exercise, Relaxation, and Health Education	-

Primary Outcome Measures

Name	Time	Method
change in inflammatory markers	within 26 weeks of enrollment

Secondary Outcome Measures

Name	Time	Method
change in psychological and physiological markers of anxiety, depression, and cardiovascular disease	within 26 weeks from enrollment

Trial Locations

Locations (1)

The Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States